Biodexa Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $; its P/E ratio is ―; Biodexa Pharmaceuticals is scheduled to report earnings on September 12, 2024, and the estimated EPS forecast is

gt;-0.01. See an overview of income statement, balance sheet, and cash flow financials.

	Jun 22	Dec 21	Jun 21	Dec 20	Jun 20
Income Statement	-
Total Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
EBIT	-	-	-	-	-
EBITDA	-	-	-	-	-
Net Income Common Stockholders	-	-	-	-	-
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	£ 6.42M	£ 10.06M	£ 4.20M	£ 7.55M	£ 4.33M
Total Assets	£ 9.68M	£ 12.91M	£ 8.28M	£ 9.82M	£ 12.00M
Total Debt	£ 713.00K	£ 766.00K	£ 812.00K	£ 260.00K	£ 3.51M
Net Debt	£ -5.71M	£ -9.29M	£ -3.39M	£ -7.29M	£ -820.00K
Total Liabilities	£ 2.19M	£ 2.46M	£ 4.52M	£ 3.10M	£ 7.45M
Stockholders Equity	£ 7.49M	£ 10.45M	£ 3.75M	£ 6.72M	£ 4.55M
Cash Flow	-
Free Cash Flow	-	-	-	-	-
Operating Cash Flow	-	-	-	-	-
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	-	-	-	-	-

Currency in GBP

Biodexa Pharmaceuticals Earnings and Revenue History

Income Statement >

Biodexa Pharmaceuticals Debt to Assets

Balance Sheet >

Biodexa Pharmaceuticals Cash Flow

Cash Flow >

Biodexa Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing